Framingham, MA, November 23, 2011-Dilon Devices, Inc. today announced that its CEO, Dan Levangie, will participate in the 23rd Annual Piper Jaffray Healthcare Conference and will present an overview of Dilon Devices at 3:10 PM on Wednesday, November 30, 2011.
The Piper Jaffray Healthcare Conference, being held on November 29 & 30, 2011 at the New York Palace Hotel, will feature 275 influential public and private companies in the biotechnology, specialty pharmaceuticals, drug discovery, medical technology, healthcare services, and medical diagnostics and devices sectors.
About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic
applications. The MarginProbe System is Dune’s first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device in the U.S.
Dilon Devices is a privately held company financed by Apax Partnerssince 2004. It has offices in the U.S., Israel, Germany and Switzerland. For more information, please visit